Multiple myeloma patients undergoing chemotherapy: Which symptom clusters impact quality of life?

AIMS AND OBJECTIVES To identify symptom clusters and examine their association with health-related quality of life. BACKGROUND Multiple myeloma patients undergoing chemotherapy suffer from disease symptoms and adverse effects during the course of the disease. However, single symptom management has little effect, and symptom management for these patients remains challenging. Symptom clusters open a new perspective and provide important clues for symptom management. DESIGN A cross-sectional study. METHOD Participants were invited to complete the Chinese version of the Memorial Symptom Assessment Scale and Quality of Life Questionnaire-core 30. Appropriate indicators were used for descriptive statistics. Principal component analysis was used to identify symptom clusters. Associations between symptom clusters and quality of life were examined with Pearson correlation coefficients, Pearson correlation matrix and multiple linear regression. This study was reported following the STROBE checklist. RESULTS A total of 177 participants were recruited from seven hospitals in this study. We identified self-image disorder, psychological, gastrointestinal, neurological, somatic and pain symptom clusters in multiple myeloma patients with chemotherapy. Approximately 97.65% of patients suffer from multiple symptom clusters. The pain, psychological and gastrointestinal symptom clusters have negatively influence on health-related quality of life. The strongest association was found with the pain symptom cluster. CONCLUSION Most of multiple myeloma patients suffer from multiple symptom clusters. When improving the multiple myeloma patients' health-related quality of life, the clinical staff should prioritise relieving the pain symptom cluster. RELEVANCE TO CLINICAL PRACTICE When multiple myeloma patients undergoing chemotherapy suffer from multiple symptom clusters, nurses should prioritise relieving the pain symptom cluster to improve their health-related quality of life. When drawing up and providing interventions, nurses should focus on the correlation among symptoms rather than single symptom. By relieving one symptom in a given cluster, other symptoms within the same symptom cluster may also be relieved.

[1]  A. Jakubowiak,et al.  Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma. , 2022, Clinical Lymphoma, Myeloma & Leukemia.

[2]  Hamid Ehsan,et al.  Evidence-based Recommendations for Induction and Maintenance Treatment of Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients. , 2022, Critical reviews in oncology/hematology.

[3]  N. Geller,et al.  Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma , 2022, American journal of hematology.

[4]  T. Chen,et al.  Symptom Clusters and Quality of Life in Cervical Cancer Patients Receiving Concurrent Chemoradiotherapy: The Mediating Role of Illness Perceptions , 2022, Frontiers in Psychiatry.

[5]  J. Laubach,et al.  Patient‐reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study , 2021, British journal of haematology.

[6]  J. Laubach,et al.  A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202) , 2021, American journal of hematology.

[7]  Yan Hu,et al.  Symptom Clusters and Quality of Life in Gastric Cancer Patients Receiving Chemotherapy. , 2021, Journal of pain and symptom management.

[8]  K. Sethares,et al.  Age and gender differences in physical heart failure symptom clusters. , 2021, Heart & lung : the journal of critical care.

[9]  J. Bay,et al.  Prevalence of Chemotherapy-Induced Peripheral Neuropathy in Multiple Myeloma Patients and its Impact on Quality of Life: A Single Center Cross-Sectional Study , 2021, Frontiers in Pharmacology.

[10]  H. Goldschmidt,et al.  Health‐related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial , 2021, British journal of haematology.

[11]  A. McCarthy,et al.  Symptom clusters experienced by breast cancer patients at various treatment stages: A systematic review , 2021, Cancer medicine.

[12]  Dean Smith,et al.  Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline , 2021, British journal of haematology.

[13]  Limei Xu,et al.  Comparison of efficacy, safety, patients’ quality of life, and doctors’ occupational stress between lenalidomide‐based and bortezomib‐based induction in patients with newly diagnosed multiple myeloma , 2021, Cancer medicine.

[14]  S. Jeon,et al.  Symptom cluster profiles following traumatic orthopedic injuries: A protocol. , 2020, Research in nursing & health.

[15]  Lichuan Zhang,et al.  Nutrition impact symptom clusters in patients with head and neck cancer receiving concurrent chemoradiotherapy. , 2020, Journal of pain and symptom management.

[16]  Shaji K. Kumar,et al.  Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  B. Navarro-Almenzar,et al.  Mieloma múltiple , 2020, Medicine - Programa de Formación Médica Continuada Acreditado.

[18]  L. Escoda,et al.  Impact of response to treatment in health-related quality of life patient-reported outcomes in elderly patients with relapsed multiple myeloma , 2020, Leukemia & lymphoma.

[19]  M. Al Qadire,et al.  Symptom Clusters’ Content, Stability and Correlation with the Quality of Life in a Heterogeneous Group of Cancer Patients: A Large-Scale Longitudinal Study , 2020, Clinical nursing research.

[20]  Jiping Li,et al.  The Correlation of Symptom Clusters and Functional Performance in Adult Acute Leukemia Patients Under Chemotherapy , 2020, Cancer nursing.

[21]  S. Sereika,et al.  Symptom Clusters in Women with Breast Cancer During the First 18 Months of Adjuvant Therapy. , 2020, Journal of pain and symptom management.

[22]  M. Davies,et al.  Mechanisms and treatment of bone pain in multiple myeloma. , 2019, Current opinion in supportive and palliative care.

[23]  Taketo Yamada,et al.  Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets , 2019, Journal of oncology.

[24]  J. Mao,et al.  Reduction of Opioid Use by Acupuncture in Patients Undergoing Hematopoietic Stem Cell Transplantation: Secondary Analysis of a Randomized, Sham-Controlled Trial. , 2019, Pain medicine.

[25]  A. Rooney.  Cluster clarity? Distinct symptom clusters predict impaired quality of life. , 2019, Neuro-oncology.

[26]  C. Simonelli,et al.  Quality of life in multiple myeloma: considerations and recommendations , 2019, Expert review of hematology.

[27]  E. Choi,et al.  Factors influencing quality of life in patients with multiple myeloma , 2019, Contemporary nurse.

[28]  Nofisat Ismaila,et al.  Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  G. Sidhu,et al.  Severe Lytic Bone Lesions in Multiple Myeloma. , 2019, The American journal of the medical sciences.

[30]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[31]  Tomoki Ito,et al.  Combined Use of Ninjin'yoeito Improves Subjective Fatigue Caused by Lenalidomide in Patients With Multiple Myeloma: A Retrospective Study , 2018, Front. Nutr..

[32]  H. Goldschmidt,et al.  From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives , 2017, Haematologica.

[33]  D. Verina,et al.  Young Adults with Multiple Myeloma. , 2017, Seminars in oncology nursing.

[34]  K. Kwekkeboom,et al.  Cancer Symptom Cluster Management. , 2016, Seminars in oncology nursing.

[35]  W. Zhuang,et al.  Symptom Clusters in Ovarian Cancer Patients With Chemotherapy After Surgery: A Longitudinal Survey , 2016, Cancer nursing.

[36]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[37]  C. la Vecchia,et al.  Prevalence of vitamin B12 deficiency in patients with plasma cell dyscrasias , 2005, Cancer.

[38]  M. Gertz,et al.  Pain, mood disturbance, and quality of life in patients with multiple myeloma. , 2001, Oncology nursing forum.

[39]  S. Paul,et al.  Symptom clusters and their effect on the functional status of patients with cancer. , 2001, Oncology nursing forum.

[40]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[41]  OUP accepted manuscript , 2021, Japanese Journal Of Clinical Oncology.

[42]  D. Thompson,et al.  Measuring the symptom experience of Chinese cancer patients: a validation of the Chinese version of the memorial symptom assessment scale. , 2009, Journal of pain and symptom management.